Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Pharmaceuticals | Free Full-Text | Biased, Bitopic, Opioid–Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction | HTML
Binding affinity, potency, and intrinsic activity of opioid ligands in... | Download Table
κ-opioid receptor - Wikipedia
Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists | Science Advances
Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking | PLOS ONE
Mu Opiate Receptor Agonist - an overview | ScienceDirect Topics
Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design | Scientific Reports
Opioid Receptor | kappa, mu Opioid Receptor
Noribogaine is a G-protein biased κ-opioid receptor agonist - ScienceDirect
Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids | PLOS ONE
Untangling the complexity of opioid receptor function | Neuropsychopharmacology
Buprenorphine Education: Technical explanation of Buprenorphine mu receptor, affinity of agonist and antagonist
Opioid receptor binding affinities and selectivities at MOP, DOP and... | Download Table
Accurate Education - Neurobiology of Opioids - Accurate Clinic
Buprenorphine: A Promising Yet Overlooked Tool
Opioid Receptor Binding Affinities of Dynorphin Analogues. | Download Table
δ-opioid receptor - wikidoc
A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain | SpringerLink
Innovation – Cara Therapeutics
Receptor binding affinity of traditional mu-opioid agonists (morphine... | Download Table
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists